全文获取类型
收费全文 | 3378篇 |
免费 | 211篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 34篇 |
妇产科学 | 60篇 |
基础医学 | 459篇 |
口腔科学 | 17篇 |
临床医学 | 366篇 |
内科学 | 767篇 |
皮肤病学 | 30篇 |
神经病学 | 371篇 |
特种医学 | 133篇 |
外科学 | 577篇 |
综合类 | 4篇 |
一般理论 | 6篇 |
预防医学 | 168篇 |
眼科学 | 39篇 |
药学 | 213篇 |
中国医学 | 10篇 |
肿瘤学 | 340篇 |
出版年
2024年 | 3篇 |
2023年 | 25篇 |
2022年 | 45篇 |
2021年 | 113篇 |
2020年 | 53篇 |
2019年 | 98篇 |
2018年 | 125篇 |
2017年 | 92篇 |
2016年 | 78篇 |
2015年 | 109篇 |
2014年 | 136篇 |
2013年 | 200篇 |
2012年 | 282篇 |
2011年 | 301篇 |
2010年 | 181篇 |
2009年 | 136篇 |
2008年 | 250篇 |
2007年 | 234篇 |
2006年 | 205篇 |
2005年 | 214篇 |
2004年 | 163篇 |
2003年 | 150篇 |
2002年 | 132篇 |
2001年 | 31篇 |
2000年 | 30篇 |
1999年 | 31篇 |
1998年 | 28篇 |
1997年 | 21篇 |
1996年 | 16篇 |
1995年 | 9篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 11篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 2篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1970年 | 2篇 |
1969年 | 3篇 |
1939年 | 1篇 |
排序方式: 共有3604条查询结果,搜索用时 15 毫秒
91.
Valérie Biran An Phan Duy Fabrice Decobert Nathalie Bednarek Corinne Alberti Olivier Baud 《Developmental medicine and child neurology》2014,56(8):717-723
The prevention of neurological disabilities following preterm birth remains a major public health challenge and efforts are still needed to test the neuroprotective properties of candidate molecules. Melatonin serves as a neuroprotectant in adult models of cerebral ischemia through its potent antioxidant and anti‐inflammatory effects. An increasing number of preclinical studies have consistently demonstrated that melatonin protects the damaged developing brain by preventing abnormal myelination and an inflammatory glial reaction, a major cause of white matter injury. The main questions asked in this review are whether preclinical data on the neuroprotective properties of melatonin are sufficient to translate this concept into the clinical setting, and whether melatonin can reduce white matter damage in preterm infants. This review provides support for our view that melatonin is now ready to be tested in human preterm neonates, and discusses ongoing and planned clinical trials. 相似文献
92.
93.
94.
95.
96.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
97.
Terrier B Krastinova E Marie I Launay D Lacraz A Belenotti P de Saint-Martin L Quemeneur T Huart A Bonnet F Le Guenno G Kahn JE Hinschberger O Rullier P Diot E Lazaro E Bridoux F Zénone T Carrat F Hermine O Léger JM Mariette X Senet P Plaisier E Cacoub P 《Blood》2012,119(25):5996-6004
Data on the clinical spectrum and therapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We analyzed data from 242 patients with noninfectious mixed CryoVas included in the French multicenter CryoVas survey. Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%), cutaneous ulcers (16%), and cutaneous necrosis (14%). A connective tissue disease was diagnosed in 30% and B-cell non-Hodgkin lymphoma in 22%, whereas the CryoVas was considered to be essential in 48%. With the use of Cox-marginal structural models, rituximab plus corticosteroids showed the greater therapeutic efficacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve complete clinical, renal, and immunologic responses and a prednisone dosage < 10 mg/d at 6 months. However, this regimen was also associated with severe infections, particularly when high doses of corticosteroids were used, whereas death rates did not differ between the therapeutic regimens. The role of each of these strategies remains to be defined in well-designed randomized controlled trials. 相似文献
98.
99.
100.
Fabrice Airaud S��bastien K��ry Isabelle Valo Ingrid Maury Dominique Bonneau Olivier Ingster St��phane Bezieau 《World journal of gastroenterology : WJG》2012,18(39):5635-5639
We describe a patient with a Homo sapiens mutL homolog 1 (MLH1)-associated Lynch syndrome with previous diagnoses of two distinct primary cancers: a sigmoid colon cancer at the age of 39 years, and a right colon cancer at the age of 50 years. The mutation identified in his blood and buccal cells, c.1771delG, p.Asp591Ilefs*25, appears to be a de novo event, as it was not transmitted by either of his parents. This type of de novo event is rare in MLH1 as only three cases have been reported in the literature so far. Furthermore, the discordant results observed between replication error phenotyping and immunohistochemistry highlight the importance of the systematic use of both pre-screening tests in the molecular diagnosis of Lynch syndrome. 相似文献